Louis Children hospital.

Funding from the National Institutes of Health and the American Cancer Society supported this research.Washington University School of full-time and volunteer faculty physicians medicine and medical staff of Barnes-Jewish and St. Louis Children hospital. The School of Medicine is one of the leading medical research, teaching and patient care institutions in the nation. Currently ranked fourth by U.S. News & World Report in the nation Through his connections with Barnes-Jewish and St. Louis Children ‘s hospitals the School of Medicine linked to BJC HealthCare.

The results, published in a recent article in the Proceedings of of the National Academy of Sciences on previous work on previous work by the working group, so that aggressive types shown in neuroendocrine tumors – seen in some types of lung, thyroid and prostate cancers – produce high levels of a chemical called GABA, a neurotransmitter.The Company has two base technology platforms;. Ceragenins or to treat infectious diseases and Barrier Repair the treatment of dermatological such as atopic dermatitis and neonatal diseases of the skin and other Ceragenin compounds of are not running in against a broad spectrum of gram-positive and -negative bacteria. We used formulating formulate Cerashield Ceragenin antimicrobial coatings for medical devices. All of Ceragenin and Cerashield products are currently available in development. Ceragenix proprietary Barrier Repair technology , invented by Dr. Peter Elias to establish a platform for the development on EpiCera which Promius Promius Pharmaceuticals in the United States through an exclusive supply and distribution arrangements arrangement.